AstraZeneca Pharma India Limited receives approval for supplying Osimertinib in India

AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (Tagrisso™).

Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.3415.05 as compared to the previous close of Rs. 3436.65. The total number of shares traded during the day was 2976 in over 566 trades.

The stock hit an intraday high of Rs. 3456.8 and intraday low of 3401. The net turnover during the day was Rs. 10202105.

Source : Equity Bulls

Keywords